REG - AstraZeneca PLC - Director/PDMR Shareholding

AstraZenecaAnnouncement

09/03/2021 15:00

RNS Number : 6809R
  
AstraZeneca PLC
  
09 March 2021
  
 

9 March 2021 15:00 GMT
 
 
Transactions by Persons Discharging Managerial Responsibilities 
 
AstraZeneca PLC (the Company) announced that, on 5 March 2021, certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) were granted awards of the Company's ordinary shares of $0.25 each (Ordinary Shares) under the terms of the AstraZeneca Deferred Bonus Plan (AZDBP) and the AstraZeneca Performance Share Plan (AZPSP), as detailed in the table below.
 



PDMR


Ordinary Shares granted under the AZDBP


Ordinary Shares granted under the AZPSP


Award price per Ordinary Share




Pascal Soriot


16,944


106,655


£68.44




Marc Dunoyer


9,057


51,828


£68.44



 
The AZDBP award represents the portion of each PDMR's annual bonus for 2020 that they are required to defer into shares. The Ordinary Shares granted under the AZDBP are subject to a three-year holding period and are due to vest on the third anniversary of grant.
 
The AZPSP award is subject to a combination of performance measures focused on scientific, commercial and financial performance. An ESG measure has also been introduced to the 2021 AZPSP performance measures, which focuses on the delivery of AstraZeneca's Ambition Zero Carbon commitments and underlines the importance the Company places on eliminating Scope 1 and Scope 2 greenhouse gas emissions by 2025. The performance measures will be assessed over a three-year performance period (1 January 2021 to 31 December 2023). The Ordinary Shares granted under the AZPSP are subject to a two-year holding period following the performance period, and are due to vest on the fifth anniversary of grant.
 
Details of the performance measures attached to the AZPSP award can be found in the Directors' Remuneration Report within the AstraZeneca Annual Report and Form 20-F Information 2020, which is available on the Company's website at www.astrazeneca.com/annualreport2020. 
 
 



1 
 


Details of the person discharging managerial responsibilities / person closely associated 
 




a) 
 


Name 
 
 


Pascal Soriot




2 
 


Reason for the notification 
 




a) 
 


Position/status 
 
 


Chief Executive Officer




b) 
 


Initial notification /Amendment 
 
 


Initial notification




3 
 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
 




a) 
 


Name 
 
 


AstraZeneca PLC




b) 
 


LEI 
 
 


PY6ZZQWO2IZFZC3IOL08




4 
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
 
 




a) 
 


Description of the financial instrument, type of instrument 
 
Identification code 
 
 


Ordinary Shares of US$0.25 each in AstraZeneca PLC
 
 
GB0009895292
 




b) 
 


Nature of the transaction 
 
 


Grants of share awards under the AstraZeneca Performance Share Plan and the AstraZeneca Deferred Bonus Plan




c) 
 


Price(s) and volume(s) 
 
 


 



Price(s)
 


Volume(s)




£68.44


123,599



 
 




d) 
 


Aggregated information 
 
 
- Aggregated volume 
 
 
- Price 
 
 


Not applicable - single transaction
 
 
 




e) 
 


Date of the transaction 
 
 


5 March 2021




f) 
 


Place of the transaction 
 
 


Outside a trading venue



 



1 
 


Details of the person discharging managerial responsibilities / person closely associated 
 




a) 
 


Name 
 
 


Marc Dunoyer




2 
 


Reason for the notification 
 




a) 
 


Position/status 
 
 


Chief Financial Officer




b) 
 


Initial notification /Amendment 
 
 


Initial notification




3 
 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
 




a) 
 


Name 
 
 


AstraZeneca PLC




b) 
 


LEI 
 
 


PY6ZZQWO2IZFZC3IOL08




4 
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
 
 




a) 
 


Description of the financial instrument, type of instrument 
 
Identification code 
 
 


Ordinary Shares of US$0.25 each in AstraZeneca PLC
 
 
GB0009895292
 




b) 
 


Nature of the transaction 
 
 


Grants of share awards under the AstraZeneca Performance Share Plan and the AstraZeneca Deferred Bonus Plan




c) 
 


Price(s) and volume(s) 
 
 


 



Price(s)
 


Volume(s)




£68.44


60,885



 
 




d) 
 


Aggregated information 
 
 
- Aggregated volume 
 
 
- Price 
 
 


Not applicable - single transaction
 
 
 




e) 
 


Date of the transaction 
 
 


5 March 2021




f) 
 


Place of the transaction 
 
 


Outside a trading venue



 
 
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca. 
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
 
 
Adrian Kemp

Company Secretary
AstraZeneca PLC
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHUKOSRAUUORAR